| Full text | |
| Author(s): |
Navarrete, Josselyn Andrea Yaguana
;
Rodriguez, Dunia
;
Kanno, Alex Issamu
;
Leite, Luciana Cezar de Cerqueira
;
Trentini, Monalisa Martins
Total Authors: 5
|
| Document type: | Journal article |
| Source: | Vaccine; v. 57, p. 7-pg., 2025-05-12. |
| Abstract | |
Tuberculosis (TB) remains a major global health issue, with current treatments relying on prolonged multidrug regimens that can reduce patient compliance, and lead to drug resistance. Immunotherapeutic vaccines against Mycobacterium tuberculosis (Mtb) offer a novel approach. We have previously shown that the recombinant BCG expressing LTAK63 adjuvant (rBCG-LTAK63) decreases bacillary load and lung inflammation in Mtb-infected mice. In this work, we further investigated specific immune mechanism induced in mice infected with Mtb and treated with rBCG-LTAK63 in combination with conventional chemotherapy; different routes of administration of rBCG-LTAK63 were evaluated, such as SC, IN, and IV. Immunotherapy with rBCG-LTAK63 induces early innate immune cells migration (predominantly NK cells and monocytes/macrophages) to distinct sites; increased IFN-gamma, TNF-alpha, and IL-17 T cells, FoxP3 expressing regulatory T cells correlating with reduced bacillary load, particularly with IN administration. The findings highlight the potential of rBCG-LTAK63 to complement TB treatment. (AU) | |
| FAPESP's process: | 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma |
| Grantee: | Luciana Cezar de Cerqueira Leite |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 19/06454-0 - Evaluation of BCG expressing adjuvant LTAK63 in a humanized mouse model as a therapeutic vaccine for Tuberculosis |
| Grantee: | Monalisa Martins Trentini |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |